Alpha 2.0
Login Register
» Authors » K OKONOGI

K OKONOGI

Explore the profile of K OKONOGI including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 76
Citations 573
Followers 0
Related Specialties
Pharmacology
Infectious Diseases
Chemistry
Top 10 Co-Authors
R Hayashi
Y Iizawa
Y Matsushita
K Itoh
A Tasaka
M Kondo
M Kuno
S Harada
A Imada
N Tamura
Published In
J Antibiot (Tokyo)
Chem Pharm Bull (Tokyo)
Antimicrob Agents Chemother
J Antimicrob Chemother
Saishin Igaku
Affiliations
Soon will be listed here.
Recent Articles
1.
Autonomic nervous activity and stress hormones induced by hyperbaric saturation diving
Hirayanagi K, Nakabayashi K, OKONOGI K, Ohiwa H
Undersea Hyperb Med . 2003 Jul; 30(1):47-55. PMID: 12841608
This study describes the changes in autonomic nervous activity and stress hormones during a hyperbaric saturation dive up to 4.1 MPa in six subjects. Their autonomic nervous activity was assessed...
2.
Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication
Takashima K, Miyake H, Furuta R, Fujisawa J, Iizawa Y, Kanzaki N, et al.
Antimicrob Agents Chemother . 2001 Nov; 45(12):3538-43. PMID: 11709336
We established a human immunodeficiency virus type 1 (HIV-1) envelope (Env)-mediated membrane fusion assay and examined the small-molecule CCR5 antagonist TAK-779 and its derivatives for their inhibitory effects on HIV-1...
3.
Optically active antifungal azoles. XII. Synthesis and antifungal activity of the water-soluble prodrugs of 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone
Ichikawa T, Kitazaki T, Matsushita Y, Yamada M, Hayashi R, Yamaguchi M, et al.
Chem Pharm Bull (Tokyo) . 2001 Sep; 49(9):1102-9. PMID: 11558595
1-[(1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone (1: TAK-456) was selected as a candidate for clinical trials, but since its water-solubility was insufficient for an injectable formulation, the quaternary triazolium salts 2 were designed as water-soluble...
4.
Studies on anti-MRSA parenteral cephalosporins. IV. A novel water-soluble N-phosphono type prodrug for parental administration
Ishikawa T, Nakayama Y, Tomimoto M, Niwa S, Kamiyama K, Hashiguchi S, et al.
J Antibiot (Tokyo) . 2001 Jun; 54(4):364-74. PMID: 11426661
A systematic approach for improving the water-solubility of anti-MRSA (methicillin-resistant Staphylococcus aureus) cephalosporin derivatives is described. We first tried to improve the water-solubility of 7beta-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-fluoromethoxyiminoacetamido]-3-[(E)-2-(1-methylimidazo[1,2-b]pyridazinium-6-yl)thiovinyl]-3-cephem-4-carboxylate (1a) by substitution of the...
5.
Studies on anti-MRSA parenteral cephalosporins. III. Synthesis and antibacterial activity of 7beta-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-alkoxyiminoacetamido-3
Ishikawa T, Kamiyama K, Nakayama Y, Iizawa Y, OKONOGI K, Miyake A
J Antibiot (Tokyo) . 2001 May; 54(3):257-77. PMID: 11372783
In the course of our exploration for a novel cephalosporin derivative having excellent antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), we modified the C-3 linked spacers of cephem derivatives bearing...
6.
Optically active antifungal azoles. X. Synthesis and antifungal activity of N
Kitazaki T, Ichikawa T, Tasaka A, Hosono H, Matsushita Y, Hayashi R, et al.
Chem Pharm Bull (Tokyo) . 2001 Jan; 48(12):1935-46. PMID: 11145148
New optically active antifungal azoles, N-14-(azolyl)phenyl]- and N-14-(azolylmethyl)phenyl]-N'-[(IR,2R)-2(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(IH-1,2,4-triazol-1-yl)propyllazolones (1, 2, 3), were prepared in a stereocontrolled manner. Compounds 1-3 showed strong antifungal activity against Candida albicans in vitro. Among them,...
7.
Studies on anti-MRSA parenteral cephalosporins. II. Synthesis and antibacterial activity of 7beta-[2-(5-amino-1,2,4- thiadiazol-3-yl)-2(Z)-alkoxyiminoacetamido]-3-(substituted imidaz
Ishikawa T, Kamiyama K, Matsunaga N, Tawada H, Iizawa Y, OKONOGI K, et al.
J Antibiot (Tokyo) . 2001 Jan; 53(10):1071-85. PMID: 11132951
In an effort to discover a novel cefozopran (CZOP) derivative having excellent antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), we performed chemical modification of the alkoxyimino moiety and imidazo[1,2-b]pyridazinium group...
8.
Studies on anti-MRSA parenteral cephalosporins. I. Synthesis and antibacterial activity of 7beta-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)- hydroxyiminoacetamido]-3-(substituted imidaz
Ishikawa T, Iizawa Y, OKONOGI K, Miyake A
J Antibiot (Tokyo) . 2001 Jan; 53(10):1053-70. PMID: 11132950
In order to improve the antibacterial activity of cefozopran (CZOP) against methicillin-resistant Staphylococcus aureus (MRSA), we initiated chemical modification to introduce a 2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-hydroxyimino acetyl group at the C-7 position and...
9.
Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1
Baba M, Miyake H, Okamoto M, Iizawa Y, OKONOGI K
AIDS Res Hum Retroviruses . 2000 Jul; 16(10):935-41. PMID: 10890354
The beta-chemokine receptor CCR5 is considered to be an attractive target for inhibition of CCR5-using (R5 or macrophage-tropic) HIV-1. However, R5 HIV-1 cannot replicate in CD4+ T cell or monocyte...
10.
Emergence of fluconazole-resistant sterol 14-demethylase P450 (CYP51) in Candida albicans is a model demonstrating the diversification mechanism of P450
Aoyama Y, Kudo M, Asai K, OKONOGI K, Horiuchi T, Gotoh O, et al.
Arch Biochem Biophys . 2000 Jun; 379(1):170-1. PMID: 10864455
No abstract available.